Biotech angels invest in therapeutics, diagnostics, synthetic biology, and tools-for-science. Because timelines are long and technical risk is high, investors almost always bring domain expertise — scientists, clinicians, former pharma operators — and screen carefully for platform versus asset plays, regulatory strategy, and capital efficiency.
Deals typically move through scientific advisor networks rather than cold intros, and angels often help with clinical-advisory introductions and follow-on into specialized life-sciences funds.
Example companies in this space:
Ginkgo Bioworks
Recursion
Moderna
Verve Therapeutics
Freenome
Neuralink
Insitro
